{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:24:20Z","timestamp":1782969860462,"version":"3.54.5"},"reference-count":34,"publisher":"Walter de Gruyter GmbH","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2025-0177_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to investigate the prevalence of macroprolactinemia and the changes in hyperprolactinemia status over time among hyperprolactinemic patients in the Turkish population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0177_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study was conducted on 3,013 patient records from a central university hospital between October 2023 and October 2024. Of these, 634 hyperprolactinemic samples (Prolactin &gt;15.2\u202f\u03bcg\/L in males, &gt;23.3\u202f\u03bcg\/L in females) were analyzed using polyethylene glycol (PEG) precipitation method. Post-PEG prolactin levels were measured using electrochemiluminescence immunoassay, with the recovery percentage (R%) calculated as the ratio of prolactin post-PEG precipitation to total prolactin, where R% values below 40\u202f% were indicative of macroprolactinemia. The change in R% values was analyzed in 63 hyperprolactinemic patients who underwent restesting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0177_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Macroprolactinemia prevalence was found as 5.67\u202f% of hyperprolactinemic patients with no macroprolactinemia cases observed at PRL levels above 85.40\u202f\u03bcg\/L. Male patients had significantly higher R% values than females (p=0.003). In the gray zone (R%: 40\u201360), 29.03\u202f% of patients were classified as truly hyperprolactinemic. Repeated tests after an average of four months showed stable R% values in most cases, with only two patients changing classification between macroprolactinemia and true hyperprolactinemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0177_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The prevalence of macroprolactinemia in hyperprolactinemic Turkish patients was relatively low. As prolactin values increase, true hyperprolactinemia is more commenly observed instead of macroprolactinemia. Short-term retesting for macroprolactinemia may not be necessary unless clinical conditions change significantly. Accurate diagnosis requires method-specific cutoffs and further prospective studies using gold-standard methods like gel filtration chromatography.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2025-0177","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T07:12:30Z","timestamp":1743750750000},"page":"1736-1741","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and re-evaluation of macroprolactinemia in hyperprolactinemic patients: a retrospective study in the Turkish population"],"prefix":"10.1515","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1632-6545","authenticated-orcid":false,"given":"Osman","family":"O\u011fuz","sequence":"first","affiliation":[{"name":"Clinical Laboratory , VKV American Hospital , Istanbul , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9706-9378","authenticated-orcid":false,"given":"Kerim Erhan","family":"Palao\u011flu","sequence":"additional","affiliation":[{"name":"Clinical Laboratory , VKV American Hospital , Istanbul , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7700-7388","authenticated-orcid":false,"given":"Said","family":"Incir","sequence":"additional","affiliation":[{"name":"Medical Biochemistry , Koc University School of Medicine , Istanbul , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"2026051215061115723_j_cclm-2025-0177_ref_001","doi-asserted-by":"crossref","unstructured":"U\u011furlu, AK, G\u00fcndo\u011fan, S\u00c7. Hiperprolaktinemisi olan pediatrik olgular\u0131n klinik \u00f6zelliklerinin ve hiperprolaktinemi etiyolojilerinin de\u011ferlendirilmesi. Dicle Med J 2024;51:128\u201334.","DOI":"10.5798\/dicletip.1451742"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_002","doi-asserted-by":"crossref","unstructured":"Gibney, J, Smith, TP, McKenna, TJ. Clinical relevance of macroprolactin. Clin Endocrinol 2005;62:633\u201343. https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02243.x.","DOI":"10.1111\/j.1365-2265.2005.02243.x"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_003","doi-asserted-by":"crossref","unstructured":"Izuchukwu, ECO, Okpara, HC, Ilechukwu, OU. Macroprolactin and macroprolactinaemia: a narrative review. Magna Sci Adv Res 2023;8:187\u201394.","DOI":"10.30574\/msarr.2023.8.1.0065"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_004","unstructured":"Lim, MH, Ho, CKM. Macroprolactin screening in 464 patients with hyperprolactinaemia. Malays J Pathol 2022;44:261\u20137."},{"key":"2026051215061115723_j_cclm-2025-0177_ref_005","doi-asserted-by":"crossref","unstructured":"Koniares, K, Benadiva, C, Engmann, L, Nulsen, J, Grow, D. Macroprolactinemia: a mini-review and update on clinical practice. F S Rep 2023;4:245\u201350. https:\/\/doi.org\/10.1016\/j.xfre.2023.05.005.","DOI":"10.1016\/j.xfre.2023.05.005"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_006","doi-asserted-by":"crossref","unstructured":"Livingston, M, Hashmi, SF, Ramachandran, S, Laing, I, Heald, A. Macroprolactin over time: is there any point in rechecking it in people with a persistently elevated serum prolactin? Clin Endocrinol 2024;100:450\u20138. https:\/\/doi.org\/10.1111\/cen.15051.","DOI":"10.1111\/cen.15051"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_007","doi-asserted-by":"crossref","unstructured":"Beltran, L, Fahie, WMN, McKenna, TJ, Kavanagh, L, Smith, TP. Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms. Clin Chem 2008;54:1673\u201381. https:\/\/doi.org\/10.1373\/clinchem.2008.105312.","DOI":"10.1373\/clinchem.2008.105312"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_008","doi-asserted-by":"crossref","unstructured":"Dirican, M, Acikgoz, HE, Sarandol, E. Evaluation of percentage recovery together with modified reference range in hyperprolactinemia. Turk J Biochem 2020;45:37\u201343.","DOI":"10.1515\/tjb-2018-0377"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_009","doi-asserted-by":"crossref","unstructured":"Olukoga, AO, Kane, JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol 1999;51:119\u201326. https:\/\/doi.org\/10.1046\/j.1365-2265.1999.00757.x.","DOI":"10.1046\/j.1365-2265.1999.00757.x"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_010","unstructured":"Westgard, QC. Quality requirements, desirable biological variation database specifications. Available from: https:\/\/westgard.com\/clia-a-quality\/quality-requirements\/biodatabase1.html [Accessed 14 Feb 2025]."},{"key":"2026051215061115723_j_cclm-2025-0177_ref_011","doi-asserted-by":"crossref","unstructured":"Melmed, S, Casanueva, FF, Hoffman, AR, Kleinberg, DL, Montori, VM, Schlechte, JA, et al.. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J\u00a0Clin Endocrinol Metab 2011;96:273\u201388. https:\/\/doi.org\/10.1210\/jc.2010-1692.","DOI":"10.1210\/jc.2010-1692"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_012","doi-asserted-by":"crossref","unstructured":"Soh, NAAC, Yaacob, NM, Omar, J, Mohammed Jelani, A, Shafii, N, Tuan, ITS, et al.. Global prevalence of macroprolactinemia among patients with hyperprolactinemia: a systematic review and meta-analysis. Int J Environ Res Publ Health 2020;17:8199. https:\/\/doi.org\/10.3390\/ijerph17218199.","DOI":"10.3390\/ijerph17218199"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_013","doi-asserted-by":"crossref","unstructured":"Rufo, E, Martinez, CS, Jimenez, AL, Fernandez, PC, Barallat, J, Granada, ML. Marked geographical variation in the prevalence of macroprolactinemia. Clin Chem Lab Med 2022;60:71\u20134. https:\/\/doi.org\/10.1515\/cclm-2021-1124.","DOI":"10.1515\/cclm-2021-1124"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_014","doi-asserted-by":"crossref","unstructured":"Sherazi, NA, Baig, MZ, Khan, AH. Frequency of macroprolactin in hyperprolactinemia. J\u00a0Coll Physicians Surg Pak 2018;28:93\u20137. https:\/\/doi.org\/10.29271\/jcpsp.2018.02.93.","DOI":"10.29271\/jcpsp.2018.02.93"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_015","doi-asserted-by":"crossref","unstructured":"Heald, AH, Blantern, E, Anderson, S, Radford, D, Qureshi, Z, Nair, S, et al.. Quantitative adjustment for macroprolactin is an integral part of laboratory assessment of hyperprolactinaemia. Exp Clin Endocrinol Diabetes 2012;120:376\u201380. https:\/\/doi.org\/10.1055\/s-0032-1304618.","DOI":"10.1055\/s-0032-1304618"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_016","doi-asserted-by":"crossref","unstructured":"Soh, NAAC, Omar, J, Mohamed, WMIW, Abdullah, MR, Yaacob, NM. Low prevalence of macroprolactinaemia among patients with hyperprolactinaemia screened using polyethylene glycol 8000. J\u00a0Taibah Univ Med Sci 2016;11:464\u20138.","DOI":"10.1016\/j.jtumed.2016.08.001"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_017","doi-asserted-by":"crossref","unstructured":"Samson, SL, Hamrahian, AH, Ezzat, S, American Association of Clinical Endocrinologists. American college of endocrinology disease state clinical review: clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia. Endocr Pract 2015;21:1427\u201335. https:\/\/doi.org\/10.4158\/ep15938.dsc.","DOI":"10.4158\/EP15938.DSC"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_018","doi-asserted-by":"crossref","unstructured":"McCudden, CR, Sharpless, JL, Grenache, DG. Comparison of multiple methods for identification of hyperprolactinemia in the presence of macroprolactin. Clin Chim Acta 2010;411:155\u201360. https:\/\/doi.org\/10.1016\/j.cca.2009.10.020.","DOI":"10.1016\/j.cca.2009.10.020"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_019","doi-asserted-by":"crossref","unstructured":"Casanueva, FF, Molitch, ME, Schlechte, JA, Abs, R, Bonert, V, Bronstein, MD, et al.. Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 2006;65:265\u201373. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02562.x.","DOI":"10.1111\/j.1365-2265.2006.02562.x"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_020","unstructured":"Beda, MK, Pisarek, H, Komorowski, J, Swietoslawski, J, Fuss, CJ, Winczyk, K. Evaluation of hyperprolactinaemia with the use of the intervals for prolactin after macroforms separation. J\u00a0Physiol Pharmacol 2014;65:359\u201364."},{"key":"2026051215061115723_j_cclm-2025-0177_ref_021","doi-asserted-by":"crossref","unstructured":"Aw, T, Lau, C. The importance of macroprolactin in the diagnosis of hyperprolactinemia. Endocrinol Diabetes Metab 2021;3:75\u20139. https:\/\/doi.org\/10.54178\/jsedmv3i3001.","DOI":"10.54178\/jsedmv3i3001"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_022","doi-asserted-by":"crossref","unstructured":"Landberg, E, Dahlstr\u00f6m, U, Alehagen, U. Serum prolactin and macroprolactin in heart failure: no relation to established laboratory or clinical parameters. Ann Clin Biochem 2011;48:51\u20136. https:\/\/doi.org\/10.1258\/acb.2010.010164.","DOI":"10.1258\/acb.2010.010164"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_023","doi-asserted-by":"crossref","unstructured":"Nguyen, KQN, Langevin, RH, McPhaul, MJ, Hashim, IA. Circulating macroprolactin exhibits molecular heterogeneity and is not exclusively an antibody complex. Clin Chim Acta 2021;514:90\u20135.","DOI":"10.1016\/j.cca.2020.12.018"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_024","doi-asserted-by":"crossref","unstructured":"Barth, JH, Lippiatt, CM, Gibbons, SG, Desborough, R. Observational studies on macroprolactin in a routine clinical laboratory. Clin Chem Lab Med 2018;56:1259\u201362. https:\/\/doi.org\/10.1515\/cclm-2018-0074.","DOI":"10.1515\/cclm-2018-0074"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_025","unstructured":"Jamaluddin, FA, Sthaneshwar, P, Hussein, Z, Othman, NA, Peng, CS. Importance of screening for macroprolactin in all hyperprolactinaemic sera. Malays J Pathol 2013;35:59."},{"key":"2026051215061115723_j_cclm-2025-0177_ref_026","unstructured":"Chen, YJ, Song, GZ, Wang, ZN. A new criteria for screening macroprolactinaemia using polyethylene glycol treatment combined with different assays for prolactin. Eur Rev Med Pharmacol Sci 2016;20:1788\u201394."},{"key":"2026051215061115723_j_cclm-2025-0177_ref_027","doi-asserted-by":"crossref","unstructured":"Fahie, WM, Smith, TP. Determination of prolactin: the macroprolactin problem. Best Pract Res Clin Endocrinol Metabol 2013;27:725\u201342. https:\/\/doi.org\/10.1016\/j.beem.2013.07.002.","DOI":"10.1016\/j.beem.2013.07.002"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_028","doi-asserted-by":"crossref","unstructured":"Hattori, N, Aisaka, K, Shimatsu, A. A possible cause of the variable detectability of macroprolactin by different immunoassay systems. Clin Chem Lab Med 2016;54:603\u20138. https:\/\/doi.org\/10.1515\/cclm-2015-0484.","DOI":"10.1515\/cclm-2015-0484"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_029","doi-asserted-by":"crossref","unstructured":"Hu, Y, Ni, J, Zhang, B, Cheng, W, Zhang, H, Ye, H, et al.. Establishment of reference intervals of monomeric prolactin to identify macroprolactinemia in Chinese patients with increased total prolactin. BMC Endocr Disord 2021;21:1\u20137. https:\/\/doi.org\/10.1186\/s12902-021-00861-z.","DOI":"10.1186\/s12902-021-00861-z"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_030","doi-asserted-by":"crossref","unstructured":"Overgaard, M, Pedersen, SM. Serum prolactin revisited: parametric reference intervals and cross-platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia. Clin Chem Lab Med 2017;55:1744\u201353. https:\/\/doi.org\/10.1515\/cclm-2016-0902.","DOI":"10.1515\/cclm-2016-0902"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_031","doi-asserted-by":"crossref","unstructured":"Coleman, K, Saleem, M. Reference intervals for serum prolactin concentrations: analytical and clinical considerations. Rev Endocr Metab Disord 2024;25:995\u20131002. https:\/\/doi.org\/10.1007\/s11154-024-09927-4.","DOI":"10.1007\/s11154-024-09927-4"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_032","unstructured":"Radavelli-Bagatini, S, Lhullier, FL, Mallmann, ES, Spritzer, PM. Macroprolactinemia in women with hyperprolactinemia: a 10-year follow-up. Neuroendocrinol Lett 2013;34:207\u201311."},{"key":"2026051215061115723_j_cclm-2025-0177_ref_033","doi-asserted-by":"crossref","unstructured":"Saparamadu, AADNS, Lam, CWL, Lim, LC, Lee, J. Prolactin assay interference by macroprolactin. Clin Lab 2021;67. https:\/\/doi.org\/10.7754\/clin.lab.2020.201108.","DOI":"10.7754\/Clin.Lab.2020.201108"},{"key":"2026051215061115723_j_cclm-2025-0177_ref_034","unstructured":"Richa, V, Rahul, G, Sarika, A. Macroprolactin; a frequent cause of misdiagnosed hyperprolactinemia in clinical practice. J\u00a0Reproduction Infertil 2010;11:161\u20137."}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0177\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0177\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:15:12Z","timestamp":1778598912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0177\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,1]]},"published-print":{"date-parts":[[2025,8,26]]}},"alternative-id":["10.1515\/cclm-2025-0177"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-0177","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]}}}